Cannabis Hyperemesis Syndrome Gains Clinical Attention Amid Rising Cases

Emergency Department Presentations Rise

Emergency departments across legal cannabis states are reporting more frequent presentations of Cannabis Hyperemesis Syndrome, particularly among daily users with five or more years of consumption history. The syndrome typically unfolds in three phases: a prodromal period with morning nausea, a hyperemetic phase with intractable vomiting, and a recovery phase following cannabis cessation.

Clinicians note the disorder's distinctive behavioral marker. Patients seek relief through prolonged hot showers or baths, often spending hours in scalding water. This compulsive bathing behavior, combined with chronic cannabis use history, forms the diagnostic triad that separates CHS from cyclic vomiting syndrome or cannabinoid-induced antiemetic paradox.

Pathophysiology Remains Contested

The mechanism by which chronic cannabinoid exposure triggers hyperemesis isn't fully understood, though hypotheses center on CB1 receptor desensitization in the hypothalamus and disrupted thermoregulation. Current research suggests prolonged THC exposure may paradoxically reverse the antiemetic effects of cannabinoids, particularly in the area postrema and nucleus tractus solitarius—brainstem regions that govern nausea and vomiting.

The hot-water compulsion likely reflects dysregulated TRPV1 receptors, which mediate both cannabinoid signaling and heat sensation. Capsaicin cream applied to the abdomen has shown some efficacy in case reports, supporting this receptor-overlap theory.

Prevalence Estimates Vary Widely

Published prevalence estimates range from 0.1% to 6% of regular cannabis users, with the wide variance reflecting inconsistent diagnostic criteria and underreporting. A 2023 Colorado study found CHS accounted for 18% of cyclic vomiting presentations in the emergency department. That's a sixfold increase from pre-legalization baselines.

Key risk factors include:

• Daily or near-daily use for three or more years
• High-potency concentrates or vaporized products
• Male sex (2:1 male-to-female ratio in most cohorts)
• Age under 50 at symptom onset

Diagnostic Challenges Persist

Misdiagnosis remains common, with patients often undergoing extensive gastrointestinal workups—including endoscopy, CT imaging, and empiric proton-pump inhibitor trials—before CHS is considered. The average time from symptom onset to correct diagnosis spans 16 months in retrospective case series, during which patients frequently present to emergency departments multiple times.

Here's the problem: the Rome IV criteria for cyclic vomiting syndrome don't include cannabis use as an exclusion criterion, complicating differential diagnosis. Some institutions now incorporate standardized CHS screening questions into triage protocols for recurrent vomiting presentations.

Treatment Protocols Evolve

Cannabis cessation is the only definitive treatment, with symptom resolution typically occurring within days to weeks of complete abstinence. Supportive care during acute episodes includes intravenous hydration, antiemetics (though traditional agents like ondansetron show limited efficacy), and benzodiazepines for anxiety.

Haloperidol and topical capsaicin have emerged as first-line symptomatic treatments in some emergency departments, based on small case series showing faster symptom resolution compared to standard antiemetic regimens. Propranolol has shown promise in case reports, possibly by modulating autonomic dysregulation.

Public Health Implications

The syndrome's rising profile has prompted calls for patient education in dispensaries and inclusion of CHS warnings in cannabis product labeling. For context on the broader regulatory landscape, see the CannIntel topic hub on Cannabis Hyperemesis Syndrome.

Colorado's Marijuana Enforcement Division considered adding CHS to mandatory point-of-sale health warnings in 2025, though the proposal stalled over industry concerns about stigmatizing daily users. No state currently mandates CHS disclosure on product packaging.

Research Gaps Remain

Prospective longitudinal studies tracking CHS incidence in legal markets are scarce, and no validated biomarkers exist for early identification of at-risk users. The National Institute on Drug Abuse has funded three ongoing cohort studies examining genetic polymorphisms in cannabinoid metabolism and CHS susceptibility.

Clinicians emphasize the need for patient registries to clarify true prevalence, identify dose-response thresholds, and assess whether product type—flower versus concentrate—modulates risk. The absence of standardized diagnostic criteria across studies hampers meta-analysis and guideline development.